Form 4: Helius Medical Technologies CEO Receives Stock Options
SEC Form 4
Dane Andreeff, CEO of Helius Medical Technologies, was granted stock options for 808,000 shares under the company's 2022 Equity Incentive Plan.
Summary
- Dane Andreeff, the President and CEO of Helius Medical Technologies, Inc., received a grant of stock options on July 2, 2024.
- The stock options are for 808,000 shares of Class A Common Stock.
- The exercise price of the options is $0.965 per share.
- 62.5% of the options vested immediately, with the remainder vesting in equal quarterly installments over the next ten quarters, starting September 30, 2024.
- The options expire on July 1, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The vesting schedule promotes long-term commitment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes the CEO to remain with the company for the long term.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like medical technology.
- The size of the grant and the vesting schedule are typical for CEO-level positions, designed to incentivize long-term performance and retention.
- Companies like Medtronic and Boston Scientific also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 07/02/2024 | Date of the stock option grant. |
| 09/30/2024 | Start date for quarterly vesting of remaining stock options. |
| 07/01/2034 | Expiration date of the stock options. |
Keywords
stock options, Helius Medical Technologies, CEO, equity incentive plan, HSDT, Dane Andreeff
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.